Abstract
Invasive fungal infections (IFIs) are an important cause of morbidity and mortality in patients with acute leukemia who are receiving chemotherapy. Primary prophylaxis with antifungal agents has become the standard of care in this setting; as a result, invasive candidiasis has shown a significant reduction. However, broad use of antifungal prophylaxis has led to an increase in breakthrough candidiasis with reduced susceptibility or resistance to fluconazole. In addition, an increase in breakthrough mucormycosis has been reported in studies of voriconazole prophylaxis. We report on a case of disseminated candidiasis and subsequent breakthrough pulmonary mucormycosis in a patient with acute myeloid leukemia undergoing consolidation chemotherapy. To the best of our knowledge, in Korea, this is the first report of these two independent IFIs occurring in a single patient.
| Original language | English |
|---|---|
| Pages (from-to) | 544-548 |
| Number of pages | 5 |
| Journal | Infection and Chemotherapy |
| Volume | 44 |
| Issue number | 6 |
| DOIs | |
| State | Published - Dec 2012 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Breakthrough fungal infection
- Candidiasis
- Invasive
- Mucormycosis
- Prophylaxis
Fingerprint
Dive into the research topics of 'A case of disseminated candidiasis and subsequent breakthrough pulmonary mucormycosis after consolidation chemotherapy for acute myeloid leukemia'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver